AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
RALEIGH, N.C., April 12, 2018 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2018 results after the market closes on Wednesday, April 25, 2018. The Company will also host a conference call on Thursday, April 26, 2018 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 2471729. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 2471729.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, an audio playback of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 15,800 employees worldwide. Since 2000, PRA has participated in approximately 3,700 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 75 drugs. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: [email protected]
INQUIRIES: Christine Rodgers, Manager - Public Relations, Corporate Communications
EMAIL: [email protected] PHONE: +1 919.786.8463
